Search Results - Therapeutic

35 Results Sort By:
Tetrahydrocarbazole derivatives having improved biological action and improved solubility as ligands of G-protein coupled receptors (GPCR)
Pathologies associated with Luteinizing hormone-releasing hormone LHRH include a number of cancers, prostate hyperplasia, endometriosis, uterine fibroids and polycystic ovary syndrome. Analogues for LHRH have been developed to treat gynecological disorders and cancers, including leuprolide and triptorelin. However, agonists of LHRH lead to total ph...
Published: 9/17/2018   |   Inventor(s): Klaus Paulini, Matthias Gerlach, Eckhard Guenther, Emmanuel Polymeropoulos, Silke Baasner, Peter Schmidt, Ronald Kuhne, Arvid Soderhall
Keywords(s):  
Category(s): Therapeutic
Bi-Functional RGD Peptide and a Co-Signaling Mechanism to Promote Therapeutic Angiogenesis
Bi-Functional RGD Peptide to Promote Therapeutic Angiogenesis, Treat Ischemic DiseasesTechnology: While previous studies have focused on the identification of biological ligands to improve the functions of endothelial cells, MUSC and Clemson University researchers have combined modern bioinformatics and a newly established peptide functionalized h...
Published: 9/6/2018   |   Inventor(s): Chung-Jen (James) Chou, Ying Mei, Jia Jia
Keywords(s):  
Category(s): Therapeutic
Glyco-Typer- A method of glycan analysis of immunocaptured proteins
Glyco-Typer- A method of glycan analysis of immunocaptured proteinsTechnology: Researchers at the Medical University of South Carolina have created a method and system that for the first time will enable the simultaneous glycan analysis of thousands of individual proteins found in complex protein mixtures such a serum and tissue samples. This metho...
Published: 8/2/2018   |   Inventor(s): Anand Mehta, Richard Drake, Brian Haab
Keywords(s):  
Category(s): Therapeutic
5HT1F receptor ligands that induce mitochondrial biogenesis
Technology: MUSC investigators have used manual curation and traditional medicinal chemistry techniques to synthesize new chemical entity analogues for 5HT1F receptors. These structurally unique novel chemical entities act as agonists to the serotonin class-1F (5HT1F) receptors and were found to be potent inducers of mitochondrial biogenesis (MB) i...
Published: 6/27/2018   |   Inventor(s): Christopher Lindsey, Craig Beeson, Rick Schnellmann, Yuri Peterson
Keywords(s):  
Category(s): Therapeutic
Organ Preconditioning with Mitochondrial Elongating Agents M1/Mdivi1 in Transplantation
M1/Mdivi1 as a novel treatment to reduce immunogenicity in organ transplantationTechnology: Addition of M1 and Mdivi1 drugs in organ preservation solutions can reduce the immunogenicity of the donor organ’s microvascular endothelial cells (ECs), thereby promoting allograft immune tolerance. Inventors at MUSC have found that the use of M1 (a m...
Published: 3/19/2018   |   Inventor(s): Satish Nadig, Carl Atkinson, Danh Tran
Keywords(s):  
Category(s): Therapeutic
Total Body Irradiation Using Pre-Existing Dose Dynamic Fields
Technology: TA library of pre-commissioned dose dynamic fields offers a simple method for delivery of total body irradiation (TBI) given in preparation for transplant. This simple technique is available for any VMAT-capable machine, regardless of the treatment room size or span of the MLCs, yet does not require complex planning or patient-specific ...
Published: 10/9/2017   |   Inventor(s): Nicholas Koch
Keywords(s):  
Category(s): Therapeutic
Cyclic Peptide Inhibitors of Lysine-Specific Demethylase 1- Sickle Cell Disease
Technology: Researchers at MUSC have used a ligand-based approach to design and synthesize a series of cyclic peptides that are effective inhibitors of LSD1, and have greater stability to proteolytic degradation than their linear homologues. For example, cyclic peptide 9 inhibits LSD1 in vitro with a Ki value of 385 nM and is significantly more sta...
Published: 9/13/2017   |   Inventor(s):  
Keywords(s):  
Category(s): Therapeutic
Mitochondrial targeted HDAC inhibitors for the treatment of heart failure and related diseases and disorders (MitoDACs)
Mitochondrial targeted HDAC inhibitors for the treatment of heart failure and related diseases and disorders (MitoDACs)Technology: Researchers at MUSC have discovered HDAC1 is present in the adult cardiac myocyte mitochondria. A series of HDAC1 inhibitors that target mitochondria have been made (MitoDACs). One of the analogs, LL-66, localizes to th...
Published: 8/22/2017   |   Inventor(s): Donald Menick, Chung-Jen (James) Chou, Daniel Herr, Xiaoyang Li
Keywords(s):  
Category(s): Therapeutic
Pharmaceuticaly Modified T cells for Adoptive Cell Therapy Against Cancer
Inventors have found that treatment of tumor-reactive human T cells with drugs that co-modulate β-catenin and PI3Kδ enhances their antitumor capacity, especially their ability to exert a long-term immune response against cancer. Th17 cells inhibited of both pathways expressed less RORγt, which, in turn, reduced their ability to sec...
Published: 7/10/2017   |   Inventor(s): Chrystal Paulos, Kinga Majchrzak, Jacob Bowers
Keywords(s):  
Category(s): Therapeutic
Antifibrotic effects of oxetanyl sulfoxides
Technology: Currently, there are only two approved therapies for Idiopathic Pulmonary Fibrosis (IPF), pirfenidone and nintedanib, which are minimally effective at slowing the disease. These treatments are not effective at all in halting or reversing the progression of IPF. Therefore, there remains a great need for more effective therapies. Research...
Published: 6/14/2017   |   Inventor(s): Carol Feghali-Bostwick, Peter Wipf
Keywords(s):  
Category(s): Therapeutic
1 2 3 4 
© 2018. All Rights Reserved. Powered by Inteum